{"schema":"hottub-news/story/v1","story":"st_afq7t4al5jwr2gybe6dq","title":"Otsuka's Taiho Starts US Filing for Zipalertinib as a First-Line Lung Cancer Combination","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/otsukas-taiho-starts-us-filing-for-zipalertinib-as-a-first-line-lung-afq7t4al5j","count":1,"items":[{"id":"n_afq7t4al5jwr2gybe6dq","seq":1247519,"kind":"article","title":"Otsuka's Taiho Starts US Filing for Zipalertinib as a First-Line Lung Cancer Combination","url":"https://tokyobrief.com/articles/otsuka-taiho-zipalertinib-fda-rtor-first-line-lung-cancer","summary":"Otsuka says Taiho has begun an FDA application for zipalertinib with chemotherapy in untreated EGFR exon 20 lung cancer, with the filing due to finish by end-2026 and no change to the company's current-year forecast.","published":"2026-10-02T01:37:49Z","seen":"2026-10-02T01:43:07Z","lang":"ja","country":"JP","source":{"id":"kite-tokyobrief-com-a5667e","name":"tokyobrief.com","domain":"tokyobrief.com","outlet":{"wikidata":"Q141513445","name":"Tokyo Brief","type":"other","designations":["newsletter"]}},"via":"kite-tokyobrief-com-a5667e","entities":[{"id":"Q19001460","name":"Koichi Otsuka","type":"org"},{"id":"Q131418163","name":"Zipalertinib","type":"other"}],"image":"https://tokyobrief.com/media/tokyo-brief-2026-10-02-otsuka-taiho-zipalertinib-fda-rtor-first-line-lung-cancer-2c4eeaa94af7f674a848925bfd34c9b63071a7505a63f2a1ef4f2c07b6ae615d.png?v=card","story":"st_afq7t4al5jwr2gybe6dq","category":"health","category_p":0.4399999976158142,"sentiment":"neutral","tone":0.1599999964237213,"political":0.20000000298023224}]}